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Univariate sensitivity analysis was done. RESULTS: Over the time horizon 
evaluated, prophylactic treatment avoids 681 cases of bleeding and 246 of joint 
damage. Total expected costs with prophylactic treatment were US$3.86M 
compared to on demand treatment US$2.09M. The incremental cost 
effectiveness ratio (ICER) for prophylactic treatment was US$2592/avoided 
bleeding and US$7172/avoided joint damage (cost-effectiveness threshold: 1 
Colombian GDP per capita = US$7235). Sensitivity analyses showed the 
robustness of the model. CONCLUSIONS: Prophylactic treatment of severe 
hemophilia B, with recombinant factor IX would be a highly cost-effective 
intervention from the social perspective.  
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OBJECTIVES: Chronic migraine produces significant societal costs and reductions 
in quality of life. OnabotulinumtoxinA is licensed in Canada for the prophylaxis 
of headaches in adults with chronic migraine. We developed a model to estimate 
the cost-effectiveness of onabotulinumtoxinA for patients with chronic migraine 
who are intolerant or refractory to two or more oral prophylaxis agents. 
METHODS: A state transition model with a three-year time horizon was 
developed to estimate the incremental impact of onabotulinumtoxinA relative to 
placebo in units of quality adjusted life years (QALYS) for adults with chronic 
migraine in Canada. Each treatment cohort was divided into health states 
defined by the number of headache days experienced per month. A societal 
perspective was taken, including cost of treatment, acute health care resource 
use, absenteeism, and presenteeism. Pooled data from the subgroup of patients 
who had previously tried two or more prophylactics in the Phase III clinical trial 
program were used to estimate the baseline health state distributions and 
transition probabilities. Quality of life and health care resource utilization were 
estimated from a large international observational study of migraine patients. 
RESULTS: Treatment with onabotulinumtoxinA produced an incremental benefit 
of 0.151 QALYs over 3 years at an incremental cost of $974 compared to placebo, 
thus resulting in an Incremental Cost Effectiveness Ratio (ICER) of $6,450/QALY. 
Results were most sensitive to hourly wage, mean lost work hours, and mean 
number of hospitalizations in the three highest headache days per month health 
states. OnabotulinumtoxinA remains cost-effective when excluding lost 
productivity costs, with an ICER of $24,504/QALY. CONCLUSIONS: In this study, 
onabotulinumtoxinA was shown to be a cost-effective treatment option and may 
be considered good value for money from a Canadian societal perspective for the 
prophylaxis of headaches in adults with chronic migraine who fail or are 
intolerant to other treatment options.  
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OBJECTIVES: Fibromyalgia is a disorder often characterized by chronic 
musculoskeletal pain over multiple regions of the body not explained by 
anatomical injury. Pregabalin is the only approved medication for fibromyalgia 
in Taiwan. This study aims to estimate the cost-effectiveness of pregabalin for 
treatment of severe fibromyalgia in Taiwan. METHODS: A decision-analytic 
model was constructed for projecting the effects and costs of pharmaceutical 
treatment of fibromyalgia sufferers in Taiwan. Treatment comparators and 
utilization patterns were provided through local physician questionnaires and a 
national key opinion leader advisory board (rheumatologist, pain specialists and 
neurologist). Costs were collected from local published data. Response (30% 
improvement over baseline in pain score and patient global impression) and 
non-response of a single patient were modeled to pregabalin 300mg or 450mg 
versus placebo and alternative medications used in practice as suggested by the 
advisory board (amitriptyline 25mg, duloxetine 60/120mg, tramadol 200mg, or 
gabapentin 1800mg) for 12 weeks, followed by a three-year Markov model 
depicting maintained response, lost response, or stopped treatment. Transition 
probabilities were retrieved from published randomized trials. Effectiveness was 
quality-adjusted life years (QALYs). Costs and QALYs were annually discounted 
at 3%. Annual costs were reported in 2013 US$. RESULTS: The base case patient 
was a 42 year old woman. Compared pregabalin 300mg and 450mg with placebo, 
the incremental cost-effectiveness ratios (ICERs) were $33,369/QALY and 
$49,040/QALY. The ICERs for pregabalin 300mg versus duloxetine 60mg/120mg, 
tramadol, or gabapentin were $33,009/QALY, $3,377/QALY, $189,956/QALY, and 
$36,318/QALY, respectively. The ICERs for pregabalin 450mg versus duloxetine 
60mg, duloxetine 120mg, tramadol, or gabapentin were $63,970/QALY, 
$39,697/QALY, $237,612/QALY, and $66,755/QALY, respectively. Both pregabalin 
300mg and 450mg had higher cost and lower QALYs than amitriptyline. The 
results are robust under probabilistic sensitivity analysis. CONCLUSIONS: 
Depending on a budgetary authority’s willingness to pay, pregabalin may be 
cost-effective against placebo and alternative treatments.  
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OBJECTIVES: Urinary incontinence (UI) secondary to a neurogenic pathology, 
including spinal cord injury (SCI) and Multiple Sclerosis (MS), is termed 
neurogenic detrusor overactivity (NDO). Patients with NDO experience a 
decrease in quality of life (QoL) and are at risk for upper urinary tract damage. 
We sought to investigate the clinical and economic impact of 
onabotulinumtoxinA treatment for UI due to NDO from the US payer perspective. 
METHODS: We developed a Markov state transition model to estimate outcomes 
and costs for anticholinergic refractory NDO patients who received 
onabotulinumtoxinA or best supportive care (BSC). Non-responding patients 
(<50% reduction in UI episodes at 6 weeks) were eligible to receive invasive 
procedures (i.e. augmentation cystoplasty or sacral neuromodulation). Patients 
could transition through six health states defined by response to initial 
treatment, invasive procedures, and death. Time in each health state was 
adjusted for patient QoL and summed to estimate quality-adjusted life years 
(QALY). We included direct medical costs related to medications and invasive 
treatments, physician visits, and catheterization. Outcomes and costs were 
compared using the incremental cost-effectiveness ratio. The time horizon of the 
model was 3 years and results were discounted at 3%. RESULTS: 
OnabotulinumtoxinA increased QALYs by 0.059 and costs by $1,466 compared to 
best supportive care, yielding an estimated ICER of $24,720/QALY. 
OnabotulinumtoxinA also decreased mean incontinence episodes per person-
year by 400, resulting in a cost of $4 per incontinence episode avoided. Model 
results were most sensitive to the probability of treatment response. The 
probabilistic sensitivity analysis indicated that at a willingness to pay of 
$50,000/QALY, onabotulinumtoxinA has a 97% probability of being cost-effective. 
In subgroup analyses of each etiology, onabotulinumtoxinA yielded an ICER of 
$32,268/QALY in MS and $2,182 in SCI. CONCLUSIONS: OnabotulinumtoxinA 
appears to be a cost-effective intervention for UI due to NDO when compared to 
best supportive care.  
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OBJECTIVES: Examine the number of hospitalizations, emergency room  
(ER) visits, fractures, and falls among patients diagnosed with Parkinson Disease 
(PD) initiating therapy with either Selegiline (SEL) or Rasagiline (RAS). METHODS: 
This study utilized data from the Truvan Health Analytics MarketScan Claims 
and Encounters Database from 1/1/2006 through 3/31/2011. Eligible patients  
filled a prescription for SEL or RAS, with first such date identified as index date, 
were diagnosed with PD (ICD-9-CM 332 or 332.0) in the 2 years post the index 
date (i.e., the post-period), and were continuously insured from 6 months prior 
(i.e., the pre-period) through the end of the post-period. Logistic regressions  
were utilized to estimate adjusted odds ratios of hospitalizations and ER visits 
(both total and PD-related) as well as odds of fractures and falls,  
while controlling for socio-demographic and clinical characteristics. The apriori 
specified level of significance was 5%. RESULTS: There were 3,864 individuals  
in the analyses (1,085 SEL; 2,779 RAS). On average, RAS patients were slightly 
younger (56.3 v 56.8 years; P=0.0320), had a significantly higher copayment 
associated with initial prescription ($44.72 v $21.36; P<0.0001) and  
were significantly more likely to have a comorbid diagnosis of high cholesterol 
(18.10% v 14.01%; P=0.0023). After controlling for patient characteristics, general 
health, disability status, comorbid diagnoses, and index prescription 
characteristics, RAS was associated with significantly lower likelihood of  
all-cause hospitalizations in the post-period (OR=0.821; 95% CI= 0.682 – 0.988), 
all-cause ER visits (OR=0.791; CI =0.677 – 0.926), PD-related ER visits (OR=0.793; 
CI=0.643 – 0.979), and falls (OR=0.552; CI=0.335 – 0.909) compared to  
patients initiating with SEL. There was not a significant difference between the 
cohorts in the odds of fracture or the odds of a PD-related hospitalization. 
CONCLUSIONS: Among patients with PD, initiation with RAS compared to SEL is 
associated with significantly fewer all-cause hospitalizations and ER visits and 
fewer falls.  
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OBJECTIVES: Patient perceptions regarding disease modifying therapies (DMT) in 
multiple sclerosis (MS) are limited to a few studies. Although DMT use has been 
shown to be beneficial in terms of preventing relapses and disability progression, 
many MS patients do not initiate therapy for unclear reasons. The objectives 
were to quantify and evaluate perceptions of MS patients not currently being 
treated with DMTs towards MS as a disease state and DMT initiation, in  
a regional health plan using the Multiple Sclerosis Medication Questionnaire 
A106 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  
  
 
(MSMQ). METHODS: A subsection of the MSMQ was administered to MS patients 
currently not on DMT. They were asked questions about MS, using the health 
beliefs model as well as items regarding their perceptions of barriers to DMT 
initiation. All items were rated on a 1 to 5 scale, with 1 being “strongly disagree” 
and 5 being “strongly agree”. Patients who answered “agree” or “strongly agree” 
were combined for chi-square analysis; t-tests were used to compare mean 
scores. RESULTS: Ninety two MS patients reported being non-DMT users. The 
mean age was 58.6 years and 78.3% were female. Only 3.3% of non-DMT users 
agreed or strongly agreed that their MS would improve without treatment.  
The highest agreed upon perceptions of barriers to DMT use dealt with possible 
side effects (58.2%) and potential high cost (51.9%). Splitting the non-DMT  
users into those who never initiated DMT and those who used to take DMT 
revealed significant differences in the impression that physicians lack 
advocating DMT use (44.7% vs. 17.1%, respectively, p<0.01) and dislike for using 
needles (24.3% vs. 46.3%, respectively, p=0.043). CONCLUSIONS: MS patients who 
are not currently on DMT may not seek or re-seek treatment for various reasons. 
It appears certain perceptions regarding MS and DMT influence behavior in 
potential DMT use.  
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OBJECTIVES: To assess sensitivity of the EQ-5D to clinical change in patients 
with Parkinson’s disease with moderate to severe L-dopa induced dyskinesias. 
METHODS: Using data from a Phase IIB, randomized, 13-week, double-blind, 
placebo-controlled, dose-response study of AFQ056, a mGluR5 antagonist, we 
identified all patients with non-missing values for the modified Abnormal 
Involuntary Movement Scale (mAIMS) and the EQ-5D at baseline and week-9 
administrations. Patients were pooled across all six treatment groups (5 active 
drug, 1 placebo). Concurrent validity and responsiveness to clinical change were 
examined for the EQ-5D utility index (range -0.59 - 1.0, with 1 representing 
perfect health), visual analog scale (VAS) (range 0 - 100, with 100 representing 
perfect health), and individual item scores (ranging from no problems to major 
problems [3]), using the mAIMS (range 0 - 24, with 24 representing severe 
dyskinesias) as the criterion variable. RESULTS: Among 197 randomized subjects, 
149 (75.6%) had non-missing values for the EQ-5D and the mAIMS at baseline and 
week 9. The mean (SD) mAIMS total score at baseline was 13.5 (4.8); this measure 
was uncorrelated with all EQ-5D item responses. At week 9, however, mAIMS 
scores were generally higher for patients who reported more problems on EQ-5D 
item responses. While mAIMS scores improved by an average of 4.8 points 
between the baseline and week-9 assessments, the mean EQ-5D utility score and 
EQ-5D VAS improved by only 0.024 and 0.05, respectively, and the number with 
better EQ-5D item responses was approximately equal to the number with worse 
responses. CONCLUSIONS: The EQ-5D demonstrated limited concurrent validity 
in Parkinson’s disease patients with moderate to severe L-dopa induced 
dyskinesias, and the EQ-5D utility index and VAS were unresponsive to clinical 
change. Evidence to support use of the EQ-5D in this population remains 
inadequate.  
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OBJECTIVES: To ascertain the psychometric properties of EuroQol Five 
Dimensional Questionnaire (EQ-5D) among primary caregivers of children with 
autism. The convergent validity, discriminant validity, known-groups validity, 
internal consistency reliability, and floor and ceiling effects of EQ-5D were 
analyzed. METHODS: Using a cross-sectional online survey design, relevant 
study information was collected from 316 primary caregivers of children with 
autism. Study participants were from families of children with autism that were 
registered with the Interactive Autism Network (IAN). Convergent validity of the 
EQ-5D was assessed through its correlation with other measures of similar 
constructs. Discriminant validity was assessed by observing the correlation of 
EQ-5D domains with theoretically unrelated constructs. Known-groups validity 
was tested by comparing EQ-5D index and VAS scores across levels of autism 
severity among the care recipients. Reliability and floor and ceiling effects of the 
EQ-5D were also tested. RESULTS: More than 60% of participants reported 
problems of ‘anxiety/depression’. Convergent and discriminant validity of the 
EQ-5D was good. Significant correlation (convergent validity) was observed 
among EQ-5D index and VAS and (SF-12v2) Physical Component Summary (PCS) 
and Mental Component Summary (MCS) scores. Caregivers’ EQ-5D index and 
VAS scores varied by levels of autism severity among care recipients, providing 
evidence of known-groups validity. Reliability assessed through Cronbach’s 
alpha was less than satisfactory; however, corrected item-total correlations were 
adequate. Floor effects were absent, but ceiling effects were seen for EQ-5D index 
scores. CONCLUSIONS: To the best of our knowledge, this is the first study to 
test the psychometric properties of the EQ-5D among caregivers of children with 
autism. The EQ-5D is a psychometrically sound tool to elicit health state 
preferences among caregivers of children with autism.  
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OBJECTIVES: Health utility of caregivers of children with autism was assessed 
using the EuroQol five-dimensional questionnaire (EQ-5D). Utility scores of 
autism caregivers were compared to norms for the general adult United States 
(US) population. Predictors of health utility were identified. METHODS: A cross-
sectional online survey design was conducted. Caregivers registered with the 
Interactive Autism Network (IAN) were approached for participation in the 
online survey. Three hundred and sixteen usable responses were received. 
Health utility among caregivers was calculated and compared with the US 
population norms using Student’s t-test. Problems in EQ-5D domains and utility 
scores were analyzed by study characteristics using Kruskal-Wallis ANOVA. 
Ordinary least square regression using a fully adjusted multivariable model was 
used to determine the factors predicting health utility of autism caregivers. The 
Bruesh-Pagan test revealed presence of heteroskedasticity. To adjust for 
heteroskedasticity, White’s robust standard error estimates were reported. 
RESULTS: Roughly 94% of caregivers who participated in the study were females. 
As compared to their counterparts in the general US population, caregivers who 
were aged 18-44 years and were females had lower utility scores (P < 0.001). 
Significant differences in utility scores were observed among caregivers. When 
compared to males, females had lower health utility. Caregivers of lower 
socioeconomic status had lower utility scores and reported more problems in 
EQ-5D domains than those from higher socioeconomic status. Caregiver burden 
was inversely correlated with health utility. Caregiver physical and mental 
health status, objective strain, education, and relationship with the care 
recipient were found to significantly predict health utility (adjusted R-squared 
~57%). CONCLUSIONS: Autism caregivers had lower health utility than the 
general adult US population. Utility scores were found to vary by both caregiver 
and care recipient characteristics. There is an immediate need to address health 
concerns among this growing population.  
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OBJECTIVES: To evaluate the United States health-related quality-of-life burden 
of multiple sclerosis (MS) as compared to other debilitating chronic conditions 
using nationally representative data from the Medical Expenditure Panel Survey 
(MEPS). METHODS: We identified a sample of non-institutionalized patients aged 
≥18 with MS (ICD-9 code 340) using MEPS data (1998-2009) and compared them to 
individuals without MS. Similarly, cohorts were generated for the following 
common debilitating chronic conditions and their respective non-condition 
control cohorts: rheumatoid arthritis (ICD-9 code 714.0), diabetes (ICD-9 code 
250.0 – 250.93), inflammatory bowel disease (ICD-9 code 555), depressive disorder 
(ICD-9 code 311), acute coronary syndrome (ICD-9 code 411.1), and asthma (ICD-9 
code 493). The incremental changes for condition versus control were estimated 
for the 12-item Short Form Health Survey (SF-12) physical and mental summary 
scores, and the SF-6D, a preference (utility) measurement adaptation of the Short 
Form-36 questionnaire. We used ordinary least squares regression (separate 
model for each chronic condition versus control comparison) and included 
adjustment for gender, race, ethnicity, region, age, insurance status, education, 
number of chronic conditions other than the analyzed chronic condition, and 
survey year. RESULTS: As compared to other debilitating chronic conditions, the 
adjusted decrement in the SF-12 physical summary score was highest for MS  
(-11.89), followed by rheumatoid arthritis (-7.23), and inflammatory bowel 
disease (-3.94). The adjusted decrement in the SF-12 mental summary score for 
MS was (-2.9), second only to depression (-8.9). The adjusted SF-6D preference 
score deduction was highest for MS (-0.11), followed by depression (-0.10) and 
rheumatoid arthritis (-0.07). The p-values were <0.05 for all listed decrements 
compared to the control cohorts. CONCLUSIONS: MS is associated with the 
lowest HRQoL compared to other debilitating chronic conditions, with the 
exception of depression on the SF-12 metal summary score, demonstrating the 
extreme burden this disease places on the patient and society.  
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OBJECTIVES: To evaluate, from patients’ perspective, the relative importance of 
attributes related to epilepsy and the AEDs used to treat it, as well as the role of 
those attributes on adherence behaviour and quality of life (QoL). METHODS: 
Patients with epilepsy from seven countries completed a discrete choice 
experiment online choosing between AEDs with varying attributes including 
concentration problems, mood changes, balance problems, sleepiness, weight 
gain, seizure frequency, and out of pocket cost. These six attributes were 
identified for inclusion through a review of the literature and product labels. 
Attribute levels were combined in an orthogonal design. Respondents also 
completed three instruments measuring QoL, health state utility (HSU) and 
medication adherence: QOLIE-31-P, EQ-5D-5L, and MMAS-8, respectively. Tri-
level attributes were transformed to a continuous scale. Choice data were 
analysed using a mixed-logit model. Willingness to pay was estimated through 
marginal rates of substitution and using purchasing power parities. Regression 
methods explored the association between preferences, QoL, and adherence. 
